- Home
- DVAX vs BTT Comparison
DVAX vs BTT Comparison
Compare DVAX & BTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DVAX | BTT |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | DVAX | BTT |
|---|---|---|
| Price | $10.94 | $22.58 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 151.1K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $330,514,000.00 | N/A |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $18.90 |
| 52 Week High | $14.63 | $21.86 |
Technical Indicators
Market Signals| Indicator | DVAX | BTT |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 53.70 |
| Support Level | $10.79 | $22.34 |
| Resistance Level | $11.10 | $22.60 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 30.00 | 72.55 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BTT BlackRock Municipal 2030 Target Term Trust
Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.